📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly uses confident language such as 'we have great confidence', 'we remain confident', 'we are determined', and provides specific figures and timelines (e.g., $360M-$400M impact by 2032, 60% behavioral/40% acute split) to show preparedness.

Q3 2025

Confident Specific

Management cited a 53% EPS increase and 13.4% revenue growth, provided detailed guidance increases and operational metrics, and expressed optimism about new hospital openings and outpatient strategies.

Q4 2025

Confident Specific

Management repeatedly used specific numbers and ranges (e.g., revenue growth of 9%, adjusted EBITDA up 10%, guidance with exact dollar and percentage ranges), detailed outlook items (e.g., $75M exchange headwind, $35M California staffing impact), and emphasized strong expense management and growth agenda. No hedging or defensive language detected.

Q1 2026 latest

Confident Specific

Management used language like 'significant acceleration', 'steady operating performance', 'encouraged', and 'optimistic' while providing specific growth percentages (9.6% revenue, 8.4% EBITDA, 16.1% EPS) and reiterating full-year guidance without revision.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains largely unchanged after this call. The core business met expectations despite seasonal headwinds, and management reaffirmed full-year guidance, suggesting confidence in the back-half ramp. The Talkspace acquisition adds a compelling long-term outpatient growth vector but introduces near-term integration risk and execution complexity. The reiteration of aggressive share repurchase plans alongside the deal signals capital allocation discipline. Key items to watch next quarter: volume recovery in both segments (especially after flu/weather), the pace of HIX-related attrition, and progress on Talkspace closing and early synergy realization. The moderation in behavioral wage growth is a positive sign for margin expansion in the second half.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED UHS Q1 2026: Revenue +9.6%, adj. EPS +16.1%; acquired Talkspace for virtual behavioral health.

Revenue & Profitability

Q1 2026 net income attributable to UHS per diluted share was $5.65, adjusted EPS $5.62. Same-facility acute care revenue increased 8.2%, behavioral revenue 7.3%. Cash from operations was $402 million. Adjusted EBITDA net of NCI increased 8.4%. The company spent $217 million on capital expenditures and repurchased 675,000 shares for $127 million.

Outlook

Management sees strong behavioral demand shifting to outpatient settings. For 2026, they expect same-facility revenue growth to become more balanced between volume and pricing as the year progresses. Key headwinds include a $75 million pre-tax impact from HIX subsidy expirations and potential California nurse staffing ratio requirements, with which UHS remains on track.

Growth Drivers

Growth is driven by the Talkspace acquisition, expansion of outpatient behavioral services, de novo hospital openings (156-bed in Florida, 178 beds in towers/replacement projects), and continued improvement in behavioral volumes. The company also benefits from technology investments in revenue cycle and operational AI. Share repurchase remains a priority, with $1.3 billion of authorization remaining.

Balance Sheet & CapEx

In Q1 2026, capital expenditures totaled $217 million. Key projects include a 156-bed de novo acute care hospital in Florida (opening May), two bed towers and a replacement hospital (178 beds, opening in Q2), a 144-bed behavioral de novo in Pennsylvania (opened Q1), and a 120-bed behavioral hospital in Missouri (planned). The company expanded its credit facility by $900 million to $1.5 billion for flexibility.

Margins

Operating expense management was solid: acute care salaries per adjusted admission increased 3.1%, supply expense 3.5%, and contract labor fell to 2.3% of revenue (down 40 bps). Behavioral wage growth moderated to ~6% (from 7-8% in 2025). Guidance implies accelerating core EBITDA growth through the year, with operating leverage from volume improvements and moderating wage pressures.

Key Risks

Risks include HIX premium non-payment (reserve taken in Q1), weather and flu impacts on volumes (200 bps on acute, 40-50 bps on behavioral), professional fee increases (managed but high single digits), potential denial levels from payers, and uncertainties around supplemental program approvals (Florida likely, California less certain). California nurse staffing ratio compliance also represents a risk.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-07-28

Q2 2026 featured strong acute care volume growth, stable behavioral health trends, and disciplined expense management. Updated 2026 guidance reflects higher Medicaid supplemental benefits but also increased liability reserves and operating losses at select facilities. Share repurchases accelerated, and outpatient expansion remains a strategic focus.

Q1 2026 Q1 2026 2026-04-28

Q1 2026 saw strong revenue and EPS growth, driven by disciplined operations, pricing, and the strategic Talkspace acquisition. Acute and behavioral segments delivered solid results despite seasonal headwinds, with continued investment in technology, new facilities, and capital returns.

Q4 2025 Q4 2025 2026-02-26

Q4 and full-year 2025 saw strong revenue, EBITDA, and EPS growth, driven by expense management, volume gains, and technology adoption. 2026 guidance projects continued growth, with headwinds from insurance exchange reductions and new California staffing rules, but ongoing investment in capacity and AI.

Q3 2025 Q3 2025 2025-10-28

Q3 2025 saw adjusted net income per share rise 53% and revenue up 13.4% year-over-year, driven by acute care growth, improved behavioral health volumes, and a $90M DC Medicaid benefit. 2025 EPS guidance was raised, with strong capital returns and continued expansion in both acute and behavioral segments.

Q2 2025 Q2 2025 2025-07-29

Q2 2025 saw strong acute care revenue and EBITDA growth, with behavioral health revenues up but volume growth lagging targets. EPS guidance was raised to $20.50 per share, while Medicaid policy changes pose long-term risks. Share repurchases and capital investments remain priorities.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.